Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,007 Cr revenue.
COGS 54.8%, employees 8.3%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.1%▲ | 10.5% |
| ROCE | 16.5%▲ | 13.8% |
| Net Margin | 15.5%▲ | 8.7% |
| EBITDA Margin | 24.3%▲ | 16.0% |
| Debt To Equity | 0.01x▼ | 0.21x |
| Rev Growth 3yr | 25.1%▲ | 5.8% |
| EPS Growth 3yr | 25.2%▲ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | ₹1,097 Cr +8.9% | ₹1,007 Cr +40.3% | ₹717 Cr +16.3% | ₹617 Cr +18.6% | ₹520 Cr |
| Other Income | ₹33 Cr +96.3% | ₹17 Cr +126.0% | ₹7 Cr +73.4% | ₹4 Cr +56.4% | ₹3 Cr |
| Total Income | ₹1,130 Cr +10.4% | ₹1,024 Cr +41.2% | ₹725 Cr +16.7% | ₹621 Cr +18.8% | ₹523 Cr |
| COGS | ₹543 Cr -1.7% | ₹552 Cr +34.1% | ₹412 Cr +24.4% | ₹331 Cr +21.3% | ₹273 Cr |
| ₹830 Cr +2.7% | ₹808 Cr +32.2% | ₹611 Cr +20.1% | ₹509 Cr +17.9% | ₹431 Cr | |
| Profit Before Tax | ₹300 Cr +39.0% | ₹216 Cr +163.9% | ₹82 Cr -27.0% | ₹112 Cr +22.7% | ₹91 Cr |
| ₹76 Cr +37.0% | ₹56 Cr +67.9% | ₹33 Cr +14.9% | ₹29 Cr +48.1% | ₹20 Cr | |
| Net Profit | ₹224 Cr +39.7% | ₹160 Cr +229.3% | ₹49 Cr -41.5% | ₹83 Cr +15.8% | ₹72 Cr |
| Profit (Owners) | ₹224 Cr +41.1% | ₹159 Cr +271.1% | ₹43 Cr -48.6% | ₹83 Cr +15.8% | ₹72 Cr |
| Minority Interest | ₹0.06 Cr -96.6% | ₹2 Cr -71.3% | ₹6 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹0.16 Cr) -19.1% | (₹0.14 Cr) +98.1% | (₹7 Cr) ↓ Decline | ₹3 Cr +62.4% | ₹2 Cr |
| EPS | ₹27.35 | ₹19.39 | ₹5.80 | ₹11.43 | ₹9.87 |
| Diluted Shares | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
No regulatory filings available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.